UHT NYSE Real Estate Investment Trusts Financials FY2016βFY2025
Universal Health Realty Income Trust had $99.2M of revenue in fiscal 2025, up 0.2% on the year before. Over five years, revenue changed +4.9% a year on average.
Last close Β· Oct 23, 2026
$37.67
0.4%Hi! I read Universal Health Realty Income Trustβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+0.2%
Only a little. Sales grew 0.2% last year.
Does it make a profit?
17.8%
Yes. It keeps 17.8% of every sale as profit.
Is debt under control?
5.8x
Heavy. Repaying its debt would take 5.8 years of operating profit.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
26.9x
One share costs 26.9 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Universal Health Realty Income Trust did it, and the next one. Share prices often move a lot on those days.
Next results
October 26, 2026
Monday Β· tomorrow
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 27, 2026 | Q2 '26 | After the market closes | 8-K β |
| Apr 27, 2026 | Q1 '26 | After the market closes | 8-K β |
| Feb 25, 2026 | Q4 '25 | After the market closes | 8-K β |
| Oct 27, 2025 | Q3 '25 | After the market closes | 8-K β |
| Jul 28, 2025 | Q2 '25 | After the market closes | 8-K β |
| Apr 28, 2025 | Q1 '25 | After the market closes | 8-K β |
| Feb 26, 2025 | Q4 '24 | After the market closes | 8-K β |
| Oct 24, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Universal Health Realty Income Trust had $99.2M of revenue in fiscal 2025, up 0.2% on the year before. Over five years, revenue changed +4.9% a year on average. Its operating margin was 35.0%, down 2.1Β pts: of every 100 in sales, about 35 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
KIRA Β· Universal Health Realty Income Trust made $17.6M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew β0.1% a year.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
KIRA Β· Universal Health Realty Income Trust returned $41.0M to shareholders in fiscal 2025. The diluted share count rose 0.2%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Universal Health Realty Income Trust owes $368M more than it holds in cash, about 5.8 years of operating profit.
Cash, debt and the ratios that show how comfortably Universal Health Realty Income Trust can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $22.5M | $7.6M | $8.2M | $7.1M | $6.7M |
| Debt incl. finance leases | $329M | $343M | $360M | $368M | $375M |
| Net debt / EBITDA | 5.4x | 5.9x | 5.9x | 5.6x | 5.8x |
| Debt / equity | 1.4x | 1.5x | 1.8x | 2.1x | 2.5x |
| Total assets | $598M | $608M | $596M | $581M | $565M |
| Total liabilities | $363M | $378M | $395M | $401M | $413M |
| Shareholders' equity | $235M | $229M | $201M | $180M | $152M |
| Net debt (β = net cash) | $307M | $335M | $351M | $361M | $368M |
KIRA Β· Its return on capital was 5.3%: every 100 invested in the business earned about 5 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
KIRA Β· Universal Health Realty Income Trust passes 4 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 6 / 7 | 4 / 7 | 4 / 7 | 5 / 7 | 4 / 7 | 4 / 7 | 4 / 7 | 5 / 7 | 4 / 7 |
| Accruals ratio | β4.5% | β0.1% | β3.8% | β4.9% | β5.0% | 11.2% | β4.3% | β4.6% | β4.7% | β5.5% |
| Altman Z'' | β | β | β | β | β | β | β | β | β | β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $67.1M | $72.3M | $76.2M | $77.2M | $78.0M | $84.2M | $90.6M | $95.6M | $99.0M | $99.2M |
| Net interest income | β$9.4M | β$10.1M | β$10.0M | β$10.5M | β$8.3M | β$8.8M | β$10.8M | β$16.9M | β$18.8M | β$18.9M |
| Operating income | $22.1M | $24.0M | $26.7M | $25.8M | $26.0M | $28.9M | $30.7M | $31.3M | $36.8M | $34.8M |
| Net income | $17.2M | $45.6M | $24.2M | $19.0M | $19.4M | $109M | $21.1M | $15.4M | $19.2M | $17.6M |
| Diluted EPS | $1.28 | $3.35 | $1.76 | $1.38 | $1.41 | $7.92 | $1.53 | $1.11 | $1.39 | $1.27 |
| Diluted shares | 0.00B | 0.00B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | $40.7M | $46.0M | $42.9M | $42.7M | $44.2M | $47.7M | $46.8M | $42.9M | $46.9M | $49.1M |
| Capital expenditure | $60.4M | $9.0M | $4.1M | $5.1M | $2.3M | $13.0M | $13.6M | $7.6M | β | β |
| Free cash flow | β$19.7M | $37.0M | $38.9M | $37.5M | $41.9M | $34.7M | $33.2M | $35.3M | β | β |
| Depreciation and amortization | $23.0M | $25.1M | $25.0M | $25.9M | $25.6M | $27.5M | $26.6M | $27.7M | $27.4M | $28.9M |
| Stock-based compensation | $0.5M | $0.5M | $0.6M | $0.7M | $0.9M | $0.9M | $0.8M | $0.8M | $0.9M | $0.9M |
| Share buybacks | β | β | β | $0.2M | $0.2M | β | β | β | β | β |
| Dividends paid | $35.1M | $36.1M | $36.8M | $37.4M | $38.0M | $38.5M | $39.2M | $39.8M | $40.4M | $41.0M |
| Dividends and buybacks | $35.1M | $36.1M | $36.8M | $37.6M | $38.2M | $38.5M | $39.2M | $39.8M | $40.4M | $41.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $3.9M | $3.4M | $5.0M | $6.1M | $5.7M | $22.5M | $7.6M | $8.2M | $7.1M | $6.7M |
| Total debt | $316M | $257M | $262M | $274M | $295M | $329M | $343M | $360M | $368M | $375M |
| Intangible assets | $23.8M | $20.6M | $17.4M | $14.6M | $11.7M | $10.0M | $9.4M | $9.1M | $7.3M | $5.6M |
| Total assets | $525M | $490M | $484M | $489M | $494M | $598M | $608M | $596M | $581M | $565M |
| Total liabilities | $333M | $279M | $285M | $307M | $335M | $363M | $378M | $395M | $401M | $413M |
| Shareholders' equity | $191M | $211M | $199M | $182M | $159M | $235M | $229M | $201M | $180M | $152M |
| Margins | ||||||||||
| Operating margin | 33.0% | 33.2% | 35.0% | 33.4% | 33.3% | 34.3% | 33.8% | 32.8% | 37.2% | 35.0% |
| EBITDA margin | 67.3% | 67.9% | 67.8% | 66.9% | 66.1% | 66.9% | 63.1% | 61.8% | 64.9% | 64.1% |
| Net margin | 25.7% | 63.1% | 31.7% | 24.6% | 24.9% | 129.7% | 23.3% | 16.1% | 19.4% | 17.8% |
| FCF margin | β29.3% | 51.1% | 51.0% | 48.7% | 53.8% | 41.3% | 36.6% | 37.0% | β | β |
| Net interest share of revenue | β13.9% | β13.9% | β13.1% | β13.7% | β10.6% | β10.5% | β11.9% | β17.7% | β19.0% | β19.0% |
| Returns | ||||||||||
| Return on capital | 3.5% | 4.1% | 4.6% | 4.5% | 4.6% | 4.2% | 4.3% | 4.5% | 5.4% | 5.3% |
| Return on equity | 9.0% | 22.7% | 11.8% | 10.0% | 11.4% | 55.4% | 9.1% | 7.2% | 10.1% | 10.6% |
| Return on assets | 3.3% | 9.0% | 5.0% | 3.9% | 4.0% | 20.0% | 3.5% | 2.6% | 3.3% | 3.1% |
| Return on tangible equity | 10.3% | 24.0% | 13.4% | 11.3% | 13.2% | 48.4% | 9.6% | 8.0% | 11.2% | 12.0% |
| Growth | ||||||||||
| Revenue growth | β | 7.9% | 5.3% | 1.3% | 1.1% | 7.9% | 7.6% | 5.5% | 3.6% | 0.2% |
| Net income growth | β | 165.0% | β47.0% | β21.6% | 2.5% | 461.4% | β80.7% | β27.0% | 24.9% | β8.4% |
| EPS growth | β | 161.7% | β47.5% | β21.6% | 2.2% | 461.7% | β80.7% | β27.5% | 25.2% | β8.6% |
| FCF growth | β | β | 5.2% | β3.4% | 11.7% | β17.2% | β4.5% | 6.4% | β | β |
| Share count change | β | 0.7% | 100,797.1% | 0.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.2% | 0.2% |
| Financial health | ||||||||||
| Net debt / EBITDA | 6.9x | 5.2x | 5.0x | 5.2x | 5.6x | 5.4x | 5.9x | 5.9x | 5.6x | 5.8x |
| Debt / equity | 1.7x | 1.2x | 1.3x | 1.5x | 1.9x | 1.4x | 1.5x | 1.8x | 2.1x | 2.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 90.0% | 12.5% | 5.3% | 6.6% | 2.9% | 15.4% | 15.0% | 8.0% | β | β |
| Stock comp / revenue | 0.7% | 0.7% | 0.7% | 0.9% | 1.2% | 1.1% | 0.9% | 0.8% | 0.9% | 0.9% |
| Payouts / FCF | β | 97.5% | 94.7% | 100.2% | 91.1% | 110.9% | 118.1% | 112.6% | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 6.0 | 4.0 | 4.0 | 5.0 | 4.0 | 4.0 | 4.0 | 5.0 | 4.0 |
| Accruals ratio | β4.5% | β0.1% | β3.8% | β4.9% | β5.0% | 11.2% | β4.3% | β4.6% | β4.7% | β5.5% |
Source: SEC EDGAR XBRL filings (CIK 0000798783). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
